A Randomized Controlled Trial of Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD) in HIV-infected Individuals

Overview

Journal Health Psychol

Specialty Public Health

Date 2009 Feb 13

PMID 19210012

Citations 222

Authors

Steven A Safren

Conall OCleirigh

Judy Y Tan

Sudha R Raminani

Laura C Reilly

Michael W Otto

Kenneth H Mayer

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate cognitive-behavioral therapy to enhance medication adherence and reduce depression (CBT-AD) in individuals with HIV.

Design: A two arm, randomized, controlled, cross-over trial comparing CBT-AD to enhanced treatment as usual only (ETAU). ETAU, which both groups received, included a single-session intervention for adherence and a letter to the patient's provider documenting her or his continued depression. The intervention group also received 10 to 12 sessions of CBT-AD.

Main Outcome Measures: Adherence to antiretroviral therapy as assessed by Medication Event Monitoring Systems (MEMs) and depression as assessed by blinded structured evaluation.

Results: At the acute outcome assessment (3-months), those who received CBT-AD evidenced significantly greater improvements in medication adherence and depression relative to the comparison group. Those who were originally assigned to the comparison group who chose to cross over to CBT-AD showed similar improvements in both depression and adherence outcomes. Treatment gains for those in the intervention group were generally maintained at 6- and 12-month follow-up assessments. By the end of the follow-up period, those originally assigned CBT-AD demonstrated improvements in plasma HIV RNA concentrations, though these differences did not emerge before the cross-over, and hence there were not between-groups differences.

Conclusions: CBT-AD is a potentially efficacious approach for individuals with HIV struggling with depression and adherence. Replication and extension in larger efficacy trials are needed.

Citing Articles

Using creativity and the arts to promote mental health in youth living with HIV in South Africa.

Hoare J, Sher R, Cullen K South Afr J HIV Med. 2025; 25(1):1656.

PMID: 39822278 PMC: 11736547. DOI: 10.4102/sajhivmed.v25i1.1656.

A Transdiagnostic Treatment to Improve Biomedical and Syndemic Outcomes in People Living With HIV.

Rogers B, Harkness A, Ivardic I, Garcia K, Fitch C, Ironson G Cogn Behav Pract. 2024; 31(4):423-436.

PMID: 39676895 PMC: 11636638. DOI: 10.1016/j.cbpra.2023.04.002.

Treatment of Psychological Symptoms in Patients with Cystic Fibrosis.

Campagna G, Tagliati C, Giuseppetti G, Ripani P J Clin Med. 2024; 13(19).

PMID: 39407865 PMC: 11476740. DOI: 10.3390/jcm13195806.

A systematic comparison of additive and interaction approaches to modeling the effects of syndemic problems on HIV outcomes in South Africa.

Lee J, Bainter S, Tsai A, Andersen L, Stanton A, Magidson J J Behav Med. 2024; 47(6):1028-1039.

PMID: 39306630 PMC: 11499001. DOI: 10.1007/s10865-024-00517-y.

Pre-implementation planning to enhance integration of HIV and behavioral health care services at two Ryan White-funded HIV care centers.

Hussen S, Byrd R, Doraivelu K, Moore S, Camp D, Wood-Palmer D Transl Behav Med. 2024; 14(10):598-610.

PMID: 39236876 PMC: 11456817. DOI: 10.1093/tbm/ibae046.

References

Liu H, Miller L, Hays R, Golin C, Wu T, Wenger N . Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr. 2006; 41(3):315-22. DOI: 10.1097/01.qai.0000197071.77482.6e. View

Kalichman S, Kelly J, Rompa D . Continued high-risk sex among HIV seropositive gay and bisexual men seeking HIV prevention services. Health Psychol. 1997; 16(4):369-73. DOI: 10.1037//0278-6133.16.4.369. View

Gifford A, Bormann J, Shively M, WRIGHT B, Richman D, Bozzette S . Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000; 23(5):386-95. DOI: 10.1097/00126334-200004150-00005. View

Catz S, Kelly J, Bogart L, Benotsch E, McAuliffe T . Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000; 19(2):124-33. View

Ironson G, OCleirigh C, Fletcher M, Laurenceau J, Balbin E, Klimas N . Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med. 2005; 67(6):1013-21. PMC: 2614887. DOI: 10.1097/01.psy.0000188569.58998.c8. View

Leserman J, Petitto J, Gu H, Gaynes B, Barroso J, Golden R . Progression to AIDS, a clinical AIDS condition and mortality: psychosocial and physiological predictors. Psychol Med. 2002; 32(6):1059-73. DOI: 10.1017/s0033291702005949. View

Dixit A, Crum R . Prospective study of depression and the risk of heavy alcohol use in women. Am J Psychiatry. 2000; 157(5):751-8. DOI: 10.1176/appi.ajp.157.5.751. View

Paterson D, Swindells S, Mohr J, BRESTER M, Vergis E, Squier C . Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133(1):21-30. DOI: 10.7326/0003-4819-133-1-200007040-00004. View

Bangsberg D, Hecht F, Charlebois E, Zolopa A, Holodniy M, Sheiner L . Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000; 14(4):357-66. DOI: 10.1097/00002030-200003100-00008. View

10.

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

11.

Montaner J, Reiss P, Cooper D, Vella S, Harris M, Conway B . A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998; 279(12):930-7. DOI: 10.1001/jama.279.12.930. View

12.

Safren S, Hendriksen E, DeSousa N, Boswell S, Mayer K . Use of an on-line pager system to increase adherence to antiretroviral medications. AIDS Care. 2003; 15(6):787-93. DOI: 10.1080/09540120310001618630. View

13.

Lyketsos C, Hanson A, Fishman M, McHugh P, Treisman G . Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. Int J Psychiatry Med. 1994; 24(2):103-13. DOI: 10.2190/URTC-AQVJ-N9KG-0RL4. View

14.

Pirl W, Roth A . Diagnosis and treatment of depression in cancer patients. Oncology (Williston Park). 1999; 13(9):1293-301; discussion 1301-2, 1305-6. View

15.

Ickovics J, Hamburger M, Vlahov D, Schoenbaum E, Schuman P, Boland R . Mortality, CD4 cell count decline, and depressive symptoms among HIV-seropositive women: longitudinal analysis from the HIV Epidemiology Research Study. JAMA. 2001; 285(11):1466-74. DOI: 10.1001/jama.285.11.1466. View

16.

Gordillo V, Del Amo J, Soriano V, Gonzalez-Lahoz J . Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999; 13(13):1763-9. DOI: 10.1097/00002030-199909100-00021. View

17.

Markowitz J, Kocsis J, Fishman B, Spielman L, Jacobsberg L, Frances A . Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry. 1998; 55(5):452-7. DOI: 10.1001/archpsyc.55.5.452. View

18.

Perkins D, Stern R, Golden R, Murphy C, Naftolowitz D, Evans D . Mood disorders in HIV infection: prevalence and risk factors in a nonepicenter of the AIDS epidemic. Am J Psychiatry. 1994; 151(2):233-6. DOI: 10.1176/ajp.151.2.233. View

19.

Dew M, Becker J, Sanchez J, Caldararo R, Lopez O, Wess J . Prevalence and predictors of depressive, anxiety and substance use disorders in HIV-infected and uninfected men: a longitudinal evaluation. Psychol Med. 1997; 27(2):395-409. DOI: 10.1017/s0033291796004552. View

20.

Page-Shafer K, DeLorenze G, Satariano W, Winkelstein Jr W . Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol. 1996; 6(5):420-30. DOI: 10.1016/s1047-2797(96)00064-6. View